Tabrecta (capmatinib) — United Healthcare
Non-small cell lung cancer (NSCLC)
Initial criteria
- age ≥ 19 years
- Diagnosis of non-small cell lung cancer (NSCLC)
- Presence of mesenchymal-epithelial transition (MET) exon 14 skipping positive tumors OR High level MET amplification in lung cancer
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tabrecta therapy
Approval duration
12 months